Patents Assigned to Synta Pharmaceuticals Corp.
  • Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
    Patent number: 8324219
    Abstract: This invention relates to certain biologically active chemical compounds, such as benzoimidazolyl-pyrazine derivatives of formula (I) or pharmaceutically acceptable salts thereof. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: December 4, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Jun Jiang, Junyi Zhang, Lijun Sun
  • Triazole compounds that modulate HSP90 activity
    Patent number: 8318790
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: November 27, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Weiwen Ying, David James, Shijie Zhang, Junghyun Chae, Teresa Przewloka, Howard P. Ng, Hao Li, Zachary Demko, Dinesh U. Chimmanamada, Chi-wan Lee, Zhenjian Du, Kevin Foley, Minghu Song, Lijun Sun, Keizo Koya, Dan Zhou, Shuzhen Qin
  • Compounds for inflammation and immune-related uses
    Patent number: 8314134
    Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: November 20, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Jun Jiang, Hao Li, David James, Dinesh Chimmanamada, Christopher Borella, Lijun Sun, Yu Xie, Mats Holmqvist, Jerome Mahiou, Zhiqiang Xia
  • Compounds inclunding substituted pyridines for inflammation and immune-related uses
    Patent number: 8314130
    Abstract: The invention relates to certain compounds including substituted pyridines, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: November 20, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Junyi Zhang, Jun Jiang, Gary Bohnert, Nha Vo, Qinglin Che, Zhiqiang Xia, Lijun Sun
  • COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20120283272
    Abstract: The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: July 19, 2012
    Publication date: November 8, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Junyi Zhang, Jun Jiang, Gary Bohnert, Nha Vo, Qinglin Che, Zhiqiang Xia, Lijun Sun
  • COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20120245186
    Abstract: Disclosed is a method for treating a subject with cancer, comprising administering to the subject an effective amount of paclitaxel or a paclitaxel analogue and an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: October 19, 2010
    Publication date: September 27, 2012
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
  • COMBINATION CANCER THERAPY WITH BIS(THIOHYDRAZIDE) AMIDE COMPOUNDS
    Publication number: 20120232134
    Abstract: Disclosed is a method of treating a subject with cancer, the method comprising the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 ?mol/m2 to 315 ?mol/m2; and a bis(thiohydrazide amide) compound in an amount between about 1473 ?mol/m2 and about 1722 ?mol/m2.
    Type: Application
    Filed: September 12, 2011
    Publication date: September 13, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Thomas A. Dahl, Matthew McLeod
  • IL-12 Modulatory compounds
    Patent number: 8263764
    Abstract: The invention relates to cyclic hydrazone compounds, compositions including the cyclic hydrazone compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: September 11, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Zachary Demko, Lijun Sun, Howard P. Ng
  • COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20120225883
    Abstract: The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, R3, R18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: May 14, 2012
    Publication date: September 6, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Shoujun Chen, Zhi-Qiang Xia, Jun Jiang, Yu Xie, Junyi Zhang
  • COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION
    Publication number: 20120208203
    Abstract: The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NF?B and/or the amount of I?B. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NF?B and/or the amount of I?B is materially unaltered.
    Type: Application
    Filed: February 7, 2012
    Publication date: August 16, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Rongzhen Lu, James Barsoum, Yumiko Wada
  • TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY
    Publication number: 20120202813
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Application
    Filed: April 20, 2012
    Publication date: August 9, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Teresa Kowalczyk Przewloka, Shijie Zhang, Kevin Foley, Zhenjian Du, Dan Zhou, Shuzhen Qin
  • IL-12 modulatory compounds
    Patent number: 8236795
    Abstract: The invention relates to heterocyclic compounds, compositions including the compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: August 7, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Elena Kostik, Teresa Przewloka, Howard P. Ng, Dinesh Chimmanamada, Zachary Demko
  • COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20120196838
    Abstract: The invention relates to certain compounds according to Formula (I): or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders and immune disorders.
    Type: Application
    Filed: January 25, 2012
    Publication date: August 2, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Jun Jiang, Junyi Zhang, Shoujun Chen, Lijun Sun
  • BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20120190853
    Abstract: The invention relates to compounds of structural formula (I) or (III): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein ring A, X1, X2, X3, X5, R1, R4, Y, Z, L, m and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: January 19, 2012
    Publication date: July 26, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Jun Jiang, Junyi Zhang, Yu Xie
  • COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20120183579
    Abstract: The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: January 17, 2012
    Publication date: July 19, 2012
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Gary Bohnert, Zhiqiang Xia, Shoujun Chen, Lijun Sun
  • Compounds for inflammation and immune-related uses
    Patent number: 8202999
    Abstract: The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, R3, R18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: June 19, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Shoujun Chen, Zhi-Qiang Xia, Jun Jiang, Yu Xie, Junyi Zhang
  • Triazole compounds that modulate HSP90 activity
    Patent number: 8188075
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of treating or inhibiting angiogenesis in a subject in need thereof and methods for blocking, occluding, or otherwise disrupting blood flow in neo vasculature, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: May 29, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Weiwen Ying, Kevin Foley
  • PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH ELESCLOMOL BASED ON HYPOXIC STATUS
    Publication number: 20120128580
    Abstract: The present invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of hypoxia in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of lactate dehydrogenase (LDH). The invention also provides methods for treating cancer in a subject by administering an effective amount of elesclomol to the subject, wherein the subject has a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.
    Type: Application
    Filed: November 18, 2011
    Publication date: May 24, 2012
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Ronald K. Blackman, Vojo Vukovic
  • PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT BASED ON HYPOXIC STATUS
    Publication number: 20120128665
    Abstract: The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention.
    Type: Application
    Filed: November 18, 2011
    Publication date: May 24, 2012
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Ronald K. Blackman, Vojo Vukovic
  • Triazole compounds that modulate HSP90 activity
    Patent number: 8183384
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: May 22, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Teresa Przewloka, Shijie Zhang, Kevin Foley, Zhenjian Du, Dan Zhou, Shuzhen Qin